Yahoo Finance4d
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
with SARS-CoV-2 and CMV peptide pools increases the proportion of CD4⁺ and CD8⁺ T-Cells expressing exhaustion markers PD-1, LAG-3, TIGIT, TIM-3, and CD39 with each stimulation cycle.
pharmaphorum3d
MSD hits a hurdle with its LAG-3 programme
MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable (MSS ...
pharmaphorum2d
BMS gets FDA OK for first LAG-3 checkpoint inhibitor
LAG-3 is a popular target, and following after is a clutch of drugs in mid-stage development, including Immutep's soluble LAG-3 protein eftilagimod alpha, Novartis/Immutep's leramilimab, Incyte's ...
Infectious Disease Advisor6d
CD4 Recovery in Advanced HIV Slower With Anti-CD4 Autoantibodies at ART Initiation
The presence of anti-CD4 autoantibodies in treatment-naive patients with advanced HIV was associated with a decreased rate of CD4 reconstitution following ART initiation.
Medscape3d
High Immune Activation in Patients With Undetectable Viral Loads and Low CD4-Cell Counts
The decrease in CD4 cells during HIV infection seems to be driven by immune activation, which does not always correlate with viral load. Experienced clinicians are all too familiar with the ...
The Scientist5d
Releasing the Brakes: The Role of Immune Checkpoint Inhibitors in Cancer Therapy
Humans have been attempting to combat cancer since the time of the Ancient Egyptians, and recent decades have seen remarkable progress. However, tumor cells have developed sophisticated ways to evade ...